EP2574338A1 - Composition de préparation cutanée pour utilisation externe ayant d'excellents effets antibactériens et antifongiques - Google Patents

Composition de préparation cutanée pour utilisation externe ayant d'excellents effets antibactériens et antifongiques Download PDF

Info

Publication number
EP2574338A1
EP2574338A1 EP10851812A EP10851812A EP2574338A1 EP 2574338 A1 EP2574338 A1 EP 2574338A1 EP 10851812 A EP10851812 A EP 10851812A EP 10851812 A EP10851812 A EP 10851812A EP 2574338 A1 EP2574338 A1 EP 2574338A1
Authority
EP
European Patent Office
Prior art keywords
composition
skin preparation
citric acid
external use
preparation composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10851812A
Other languages
German (de)
English (en)
Other versions
EP2574338A4 (fr
Inventor
Chung Hyun Jung
Nam Woong Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2574338A1 publication Critical patent/EP2574338A1/fr
Publication of EP2574338A4 publication Critical patent/EP2574338A4/fr
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/362—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A61K8/0233—Distinct layers, e.g. core/shell sticks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24—Phosphorous; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A61Q1/04—Preparations containing skin colorants, e.g. pigments for lips
    • A61Q1/06—Lipsticks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair

Definitions

  • the present invention relates to a skin preparation composition for external use with an excellent antibacterial effect, and more specifically, to a skin preparation composition for external use with excellent antibacterial and antifungal effects against bacteria and fungi, comprising a first composition containing citric acid as an active ingredient and a second composition containing trisodium phosphate as an active ingredient.
  • Skin is a part of the body directly exposed to an outer environment and serves to control water evaporation and protect the body from external infection as well as protect important organs of the body as a protective layer. Due to coexisting of Malassezia fungi causing atopy with other bacteria such as Staphylococcus aureus, Staphylococcus epidermidis and Propionibacterium acne in the skin, when the fungi cause atopy, the bacteria worsen skin disorder caused by atopy. Therefore, it is needed to develop a skin preparation composition for external use having antibacterial effect for stopping bacteria from reproduction or sterilizing bacteria and antifungal effect for stopping fungi such as Malassezia from reproduction at the same time.
  • Citric acid is one of multibasic carboxylic acid having a hydroxyl group of chemical formula of C 6 H 8 O 7 , and is contained in seeds or juice of many plants in free acid form.
  • Citric acid fermentation is characterized by citric acid accumulation in a culture solution when microorganisms are cultured with saccharides as a substrate, and most of citric acid currently produced is made by this method.
  • the citric acid may be added to foods or used as an analysis reagent or a blood coagulating agent.
  • Korean Patent Publication No. 2007-0002718 discloses a cosmetic composition containing a softened natural petal, wherein the citric acid is used to soften the natural petal.
  • Korean Patent Publication No. 2005-0042199 discloses an organopolysiloxane polymer containing a glycerin derivative, characterized in that it can take up a liquid oil in an amount by weight not smaller than that of itself and be swollen therewith
  • Korean Patent Publication No. 2007-0097647 discloses a shampoo composition for hair growing, characterized in that a raw material for hair growing is prepared by mixing xanthium strumarium fruit extract with swertia herb extract.
  • Korean Patent Publication No. 1999-0013555 discloses a cosmetic composition
  • a cosmetic composition comprising: A) a cosmetically acceptable carrier; and B) 0.05 to 3.0 % by weight of a ⁇ -1,3-scleroglucan having a three-dimensional cross-linked triple helix structure based on the total weight of the composition.
  • a skin preparation composition for external use which has antibacterial effect for stopping bacteria from reproduction or sterilizing bacteria and antifungal effect for stopping fungi such as Malassezia from reproduction at the same time, can be prepared by separately storing citric acid and trisodium phosphate and mixing them together just before use.
  • an object of the present invention is to provide a skin preparation composition for external use with excellent antibacterial and antifungal effects.
  • the present invention provides a skin preparation composition for external use with excellent antibacterial and antifungal effects, comprising a first composition containing citric acid as an active ingredient and a second composition containing trisodium phosphate as an active ingredient.
  • FIG. 1 is a perspective view of a soap formulation comprising a first composition containing citric acid and a second composition containing trisodium phosphate according to the present invention.
  • FIG. 2 is a perspective view of a lipstick formulation comprising a first composition containing citric acid and a second composition containing trisodium phosphate according to the present invention.
  • FIG. 3 is a graph showing the growth curve of Streptococcus mitis as the result of Test Example 2 [A: citric acid 0.4 g + trisodium phosphate 0.64 g (pH 6.0), B: trisodium phosphate 0.64 g + 5N HCl (pH 6.0), C: citric acid 0.4 g + 5N NaOH (pH 6.0), D: 5N HCl (pH 6.0) and E: broth control group (pH 7.3)].
  • FIG. 4 is an image of the growth medium of Pityrosporum ovale as the result of Test Example 6 [from the left side of the image, citric acid+trisodium phosphate (pH 5.0), citric acid (pH 4.0), trisodium phosphate (TSP, pH 8.4), a control group (In) injected with only bacteria without a test compound, and a control group (Nin) containing only medium without injecting bacteria].
  • FIG. 5 is a graph showing the growth curve of Staphylococcus haemolyticus as the result of Test Example 7 [A: citric acid 8.0 mg + trisodium phosphate 20 mg/ml (pH 6.0), B: trisodium phosphate 20 mg/ml (pH 6.0), C: citric acid 8.0 mg + 5N NaOH (pH 6.0), D: 5N HCl (pH 6.0), E: broth control group (pH 7.3)].
  • FIG. 6 is a graph showing the growth curve of Peptococcus niger as the result of Test Example 8 [A: citric acid 8.0 mg + trisodium phosphate 18.5 mg/ml (pH 6.0), B: trisodium phosphate 6.4 mg/ml (pH 6.0), C: citric acid 8.0 mg + 5N NaOH (pH 6.0), D: 5N HCl (pH 6.0), E: culture medium control group (pH 7.3)].
  • citric acid having bacteriostatic or antibacterial effect against bacteria and trisodium phosphate having bacteriostatic effect against Malassezia are used at the same time, acidic and alkaline environments are formed at the same time in microenvironment of the skin, and the Malassezia is inhibited under micro alkaline environment and the bacteria are inhibited under micro acidic environment.
  • citric acid has strong antibacterial or bacteriostatic effect
  • trisodium phosphate has bacteriostatic effect by removing mineral ingredients from the surrounding environment.
  • the present invention relates to a skin preparation composition for external use with excellent antibacterial and antifungal effects against bacteria and fungi, comprising a first composition containing citric acid as an active ingredient and a second composition containing trisodium phosphate as an active ingredient.
  • the first composition may comprise citric acid in an amount of 0.1 ⁇ 10 % by weight based on the total weight of the composition. If the amount of citric acid is less than 0.1 % by weight, it is difficult to obtain the desired antibacterial effect, and if the amount thereof is more than 10 % by weight, it may cause skin irritation or it is difficult to obtain formulation stability.
  • the second composition may comprise trisodium phosphate in an amount of 0.1 ⁇ 10 % by weight based on the total weight of the composition. If the amount of trisodium phosphate is less than 0.1 % by weight, it is difficult to obtain the desired antifungal effect, and if the amount thereof is more than 10 % by weight, it may cause skin irritation or it is difficult to obtain formulation stability.
  • ingredients of the first composition and the second composition except citric acid and trisodium phosphate may be the same, or different from each other according to the formulation, and may be easily selected from ingredients commonly used in the art by person skilled in the art.
  • citric acid acts intensively on bacteria
  • trisodium phosphate acts on fungi. Therefore, they respectively form an acidic environment and an alkaline environment at microenvironment of the skin due to separate actions of the two ingredients, and fungi are inhibited under micro alkaline environment and bacteria are inhibited under micro acidic environment when the two ingredients are used together just before use, rather than when they were mixed together in advance during preparation. Therefore, citric acid and trisodium phosphate should be stored separately and be mixed together just before use to obtain the best effect.
  • first composition and the second composition may be manufactured as products by being respectively packed in separate containers, or the first composition and the second composition may be encapsulated into microcapsules, nanocapsules, liposomes or the like, known in the art, so as to be mixed when using thereof, but not limited thereto.
  • the skin preparation composition for external use may be formulated to a cosmetic preparation such as a skin softener, a skin toner, a nourishing toner, a nourishing cream, a massage cream, an essence, an eye cream, an eye essence, a lotion, a lipstick, a powder, a baby powder, a body lotion, a body cream, a body oil and a body essence; a personal cleanser such as a soap, a cleansing cream, a cleansing lotion, a cleansing foam, a cleansing water and a body cleanser; a hair composition such as a hair nourishing toner, a hair essence, a hair serum, a scalp treatment, a hair treatment, a hair conditioner, a hair shampoo and a hair lotion; a tablet; and the like, but not limited thereto.
  • Each of the formulations of the skin preparation composition for external use may comprise various ingredients mixed to common personal cleanser compositions according to its formulation or its final purpose, and kinds and amounts of the ingredients may be easily selected by a person skilled in the art
  • the skin preparation composition for external use may be formulated to the form of a two-layered tablet prepared by combining a first layer comprising the first composition containing citric acid and a second layer comprising the second composition containing trisodium phosphate using a binder commonly used in the art.
  • a neutral toner which has pH around 7.1 and does not irritate eyes, may be prepared by dissolving the two-layered tablet in water so that the citric acid contained in the first composition and the trisodium phosphate contained in the second composition are melted out at the same time, and the prepared toner may be used for washing face.
  • the skin preparation composition for external use may be formulated to a soap comprising the first composition and the second composition simultaneously by preparing a soap base containing the first composition and a soap base containing the second composition separately without mixing thereof together followed by combining them using a binder commonly used in the art.
  • the skin preparation composition for external use may be formulated to a lipstick comprising the first composition and the second composition simultaneously by preparing a lipstick containing the first composition and a lipstick containing the second composition followed by combining them using a binder commonly used in the art.
  • the skin preparation composition for external use may be formulated to a commercial baby powder or a commercial foot deodorizing powder, comprising the first composition and the second composition.
  • the skin preparation composition for external use may be formulated to a personal cleanser composition such as a shampoo.
  • a personal cleanser composition such as a shampoo.
  • representative base ingredients and additives used for the shampoo composition will be described.
  • the shampoo composition may comprise a synthetic surfactant as an ingredient for cleansing, a preservative and water.
  • the synthetic surfactant used in the present invention may be any one selected from a group consisting of an anionic surfactant, an amphoteric surfactant and a nonionic surfactant.
  • the synthetic surfactant may be used in an amount of 10 ⁇ 70 % by weight, preferably 10 ⁇ 30 % by weight, based on the total amount of the composition.
  • the synthetic anionic surfactant is alkyl and alkyl ether sulfate such as sodium lauryl sulfate, ammonium lauryl sulfate, triethanolamine lauryl sulfate, polyoxyethylene sodium lauryl sulfate and polyoxyethylene ammonium lauryl sulfate.
  • the synthetic amphoteric surfactant is alkyl betaine and alkyl amidopropyl betaine such as cocodimethyl carboxymethyl betaine, lauryldimethyl carboxymethyl betaine, lauryldimethyl alpha-carboxyethyl betaine, cetyldiemthyl carboxymethyl betaine and cocoamido propyl betaine.
  • the synthetic nonionic surfactant is alkanol amide and amine oxide such as lauryl diethyl amine oxide, palm oil alkyldimethyl amine oxide, lauric acid diethanlamide, palm oil fatty acid diethanolamide and palm oil fatty acid monoethanolamide.
  • the said surfactants may be used alone or in combination.
  • Optional ingredients which may be used in the composition of the present invention, are common optional ingredients broadly known to those skilled in the art to maintain basic properties and quality.
  • the optional ingredients may be a pearlescent agent, a preservative, a viscosity controlling agent, a pH controlling agent, a perfume, a hair conditioning agent and the like.
  • the pearlescent agent may be glycol distearate, glycol monostearate, fatty acid and the like, and it may be used in an amount of 0.1 ⁇ 10 % by weight, preferably 1.0 ⁇ 5.0 % by weight, based on the total amount of the composition.
  • the preservative may be methyl paraoxybenzoate, propyl paraoxybenzoate, sodium benzoate, methylchloroisothiazolinone, methylisothiazolinone and the like, and it may be used alone or in combination of two or more in an amount of 0.01 ⁇ 5.0 % by weight, preferably or % by weight, based on the total amount of the composition.
  • the viscosity controlling agent may be an amide-based nonionic surfactant such as cocoamide MEA (CME), cocoamide DEA (CDE) and sodium chloride, and it may be used in an amount of 0.01 ⁇ 10 % by weight, preferably 0.05 ⁇ 5 % by weight, based on the total amount of the composition.
  • CME cocoamide MEA
  • CDE cocoamide DEA
  • sodium chloride sodium chloride
  • the pH controlling agent may be sodium phosphate, disodium phosphate, citric acid, sodium citrate and the like, and it may be used in an amount of 0.01 ⁇ 5.0 % by weight, preferably 0.05 ⁇ 2.0 % by weight, based on the total amount of the composition.
  • the hair conditioning agent may be dimethicone base, di-C 12-13 alkyl malate, cationic polymer and the like, and it may be used alone or in combination of two or more in an amount of 0.1 ⁇ 10 % by weight, preferably 0.5 ⁇ 5 % by weight, based on the total amount of the composition.
  • the shampoo composition according to the present invention comprising the said ingredients may be used according to common directions, and its frequency of use may be different depending on user's scalp condition or taste.
  • BHI broth Brain Heart Infusion broths
  • citric acid 0.4 g, trisodium phosphate 0.64 g, 5N HCl and 5N NaOH according to the following prescriptions listed in Table 2, and the results thereof were shown in the following Table 2 and FIG. 3 .
  • the following control group is a broth not injected with the bacteria.
  • Streptococcus mutans (KCTC 3065) was observed in BHI broths containing citric acid 0.4 g, trisodium phosphate 0.64 g, 5N HCl and 5N NaOH according to the following prescriptions listed in Table 3, and the results thereof were shown in the following Table 3.
  • the following control group is a broth not injected with the bacteria.
  • citric acid pH 4.0
  • trisodium phosphate TSP, pH 8.4
  • citric acid+trisodium phosphate pH 5.0
  • Leeming & Notman medium 1 L containing glucose 10 g, peptone 10 g, bile salts 8 g, yeast extract 2 g, glycerol 1 monostearate 0.5 g, glycerol 10 ml and Tween 80 (1.5%) 15 ml, and 0.1 ml of Pityrosporum ovale (Malassezia furfur), which is a kind of fungi known for causing atopy, was injected to each group.
  • Pityrosporum ovale Malassezia furfur
  • the resulting medium was incubated at 32°C for 3 days and observed, and the results were shown in FIG. 4 [from the left side of the image, citric acid+trisodium phosphate (pH 5.0), citric acid (pH 4.0), trisodium phosphate (TSP, pH 8.4), control group (In) injected with only bacteria without test compounds, and control group (Nin) containing only medium without injecting bacteria].
  • Staphylococcus haemolyticus which are isolated from human keratinocytes at a high rate and cause skin irritation, was observed in BHI broths respectively containing combinations of citric acid 8.0 mg, trisodium phosphate 20 mg/ml, 5N HCl and 5N NaOH, and the results were shown in FIG. 5 [A: citric acid 8.0 mg + trisodium phosphate 20 mg/ml (pH 6.0), B: trisodium phosphate 20 mg/ml (pH 6.0), C: citric acid 8.0 mg + 5N NaOH (pH 6.0), D: 5N HCl (pH 6.0), E: broth control group (pH 7.3)].
  • a nourishing toner of Formulation Example 1 was prepared by a conventional method according to the prescription listed in Table 6 (Unit: % by weight).
  • a skin softener of Formulation Example 2 was prepared by a conventional method according to the prescription listed in Table 7 (Unit: % by weight).
  • Table 7 Ingredient Content First Composition Citric acid 1.0 Glycerin 3.0 Butylene glycol 2.0 Propylene glycol 2.0 Carboxy vinyl polymer 0.1 PEG 12 nonylphenyl ether 0.2 Polysorbate 80 0.4 Ethanol 10.0 Triethanolamine 0.1 Preservative, coloring, perfume Appropriate amount Purified Water Residual amount Second Composition Trisodium phosphate 1.0 Glycerin 3.0 Butylene glycol 2.0 Propylene glycol 2.0 Carboxy vinyl polymer 0.1 PEG 12 nonylphenyl ether 0.2 Polysorbate 80 0.4 Ethanol 10.0 Triethanolamine 0.1 Preservative, coloring, perfume Appropriate Amount Purified Water Residual amount
  • a nourishing cream of Formulation Example 3 was prepared by a conventional method according to the prescription listed in Table 8 (Unit: % by weight).
  • Table 8 Ingredient Content First Composition Citric acid 1.0 Polysorbate 60 1.5 Sorbitan Sesquioleate 0.5 PEG 60 hydrogenated castor oil 2.0 Liquid paraffin 10.0 Squalane 5.0 Caprylic/Capric triglycerides 5.0 Glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservative, coloring, perfume Appropriate amount Purified Water Residual amount Second Composition Trisodium phosphate 1.0 Polysorbate 60 1.5 Sorbitan Sesquioleate 0.5 PEG 60 hydrogenated castor oil 2.0 Liquid paraffin 10.0 Squalane 5.0 Caprylic/Capric triglycerides 5.0 Glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservative, coloring, perfume Appropriate amount Purified Water Residual amount
  • a massage cream of Formulation Example 4 was prepared by a conventional method according to the prescription listed in Table 9 (Unit: % by weight).
  • a lipstick of Formulation Example 5 was prepared by a conventional method according to the prescription listed in Table 10 (Unit: % by weight).
  • Citric acid 1.0 Candelilla wax 7.0 Beeswax 5.0 Polyglyceryl-2-triisostearate 25.0 Castor Oil Residual amount Hydrogenated polyisobutene 10.0 C10-11 isoparaffin 2.0 Silicone gel 1.0 Vitamin E acetate 2.0 Titanium dioxide 3.0 Iron oxide 5.3 FD & C yellow #5 aluminum-lake 4.5 D & C red #7 calcium-lake 1.2 Talc 4.0 Silica 5.0 Preservative Appropriate amount Perfume 0.2 Second Composition Trisodium phosphate 1.0 Candelilla wax 7.0 Beeswax 5.0 Polyglyceryl-2-triisostearate 25.0 Castor Oil Residual amount Hydrogenated polyisobutene 10.0 C10-11 isoparaffin 2.0 Silicone gel 1.0 Vitamin E acetate 2.0 Titanium dioxide 3.0 Iron oxide 5.3 FD & C yellow #5 aluminum-lake 4.5 D & C red #7 calcium-lake 1.2 Talc 4.0 Silica 5.0 Preservative Appropriate
  • a shampoo of Formulation Example 6 was prepared by a conventional method according to the prescription listed in Table 11 (Unit: % by weight).
  • Citric acid 1.0 Ammonium lauryl sulfate 10.0 Polyoxyethylene ammonium lauryl sulfate 5.0 Cocoamidopropyl Betaine 2.0 Trihydroxystearin 0.15 Cocoyl monoethanolamide 0.8 Guar Hydroxypropyltrimonium Chloride 0.2 Methyl paraben 0.1 Preservative, coloring, perfume Appropriate amount Dimethicone 1.0 Purified Water Residual amount Second Composition Trisodium phosphate 1.0 Ammonium lauryl sulfate 10.0 Polyoxyethylene ammonium lauryl sulfate 5.0 Cocoamidopropyl Betaine 2.0 Trihydroxystearin 0.15 Cocoyl monoethanolamide 0.8 Guar Hydroxypropyltrimonium Chloride 0.2 Methyl paraben 0.1 Preservative, coloring, perfume Appropriate amount Dimethicone 1.0 Purified Water Residual amount
  • Citric acid 100 mg, lactose 400 mg, corn starch 400 mg and magnesium stearate 2 mg were mixed together followed by tableting them using a tableting machine according to a conventional method for preparing a tablet, obtaining a tablet containing citric acid.
  • Trisodium phosphate 100 mg, lactose 400 mg, corn starch 400 mg and magnesium stearate 2 mg were mixed together followed by tableting them using a tableting machine according to a conventional method for preparing a tablet, obtaining a tablet containing trisodium phosphate. Then, the tablet containing trisodium phosphate was combined with the tablet containing citric acid using a binder to obtain a two-layered tablet.
  • the tablet prepared in Formulation Example 7 10 g was dissolved in water 990 cc to obtain a neutral toner, which has pH around 7.1 and does not irritate eyes.
  • the toner can be used for washing face.
  • Citric acid 5 g, palm oil fatty acid 40 ml and palm kernel fatty acid 20 ml were put into a reaction tank and heated to 80°C while maintaining a pedal at around 100 RPM.
  • sodium hydroxide solution 17 ml was slowly added thereto.
  • soap was slowly formed, and the temperature of the content increased to 90°C or more due to neutralization reaction of soap.
  • the pedal was maintained at 150 RPM to prevent coagulation of the content.
  • the resulting content was dried to obtain a soap containing citric acid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cosmetics (AREA)
EP10851812.7A 2010-05-20 2010-05-20 Composition de préparation cutanée pour utilisation externe ayant d'excellents effets antibactériens et antifongiques Withdrawn EP2574338A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2010/003201 WO2011145765A1 (fr) 2010-05-20 2010-05-20 Composition de préparation cutanée pour utilisation externe ayant d'excellents effets antibactériens et antifongiques

Publications (2)

Publication Number Publication Date
EP2574338A1 true EP2574338A1 (fr) 2013-04-03
EP2574338A4 EP2574338A4 (fr) 2014-02-12

Family

ID=44991846

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10851812.7A Withdrawn EP2574338A4 (fr) 2010-05-20 2010-05-20 Composition de préparation cutanée pour utilisation externe ayant d'excellents effets antibactériens et antifongiques

Country Status (7)

Country Link
US (2) US20130064872A1 (fr)
EP (1) EP2574338A4 (fr)
JP (1) JP2013526565A (fr)
CN (1) CN102958520A (fr)
BR (1) BR112012029418A2 (fr)
CA (1) CA2799393A1 (fr)
WO (1) WO2011145765A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
MY179756A (en) * 2013-10-03 2020-11-12 Dow Pharmaceutical Sciences Stabilized efinaconazole formulations
JP6611014B2 (ja) 2013-11-22 2019-11-27 ボシュ ヘルス アイルランド リミテッド 抗感染方法、抗感染組成物、および抗感染装置

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001017495A1 (fr) * 1999-09-09 2001-03-15 The Boots Company Plc Composition cosmetique contre les radicaux libres
US20090068219A1 (en) * 2007-09-10 2009-03-12 3Lab, Inc. Anti-wrinkle hormone-type cosmetic composition
JP2009067712A (ja) * 2007-09-12 2009-04-02 Arimino Kagaku Kk 毛髪変形処理用消臭剤
JP2009235022A (ja) * 2008-03-28 2009-10-15 Kose Corp マッサージ化粧料
WO2010033800A2 (fr) * 2008-09-19 2010-03-25 Alacrity Biosciences, Inc. Formulations stabilisant la tétracycline
KR20100043453A (ko) * 2008-10-20 2010-04-29 (주)아모레퍼시픽 천연색소를 함유하는 유중수형 립메이크업 조성물

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0860198A (ja) * 1994-08-22 1996-03-05 Sanwa Kagaku Kenkyusho Co Ltd 多層形状固形石鹸
JPH09187220A (ja) * 1996-01-09 1997-07-22 Meiyuu Sangyo Kk 食品保存用組成物
DE69715444T2 (de) * 1996-07-10 2003-04-30 Steris Inc N D Ges D Staates D Triclosan enthaltende hautreinigungsmittel mit verbesserter wirksamkeit
US5965501A (en) * 1997-03-28 1999-10-12 Lever Brothers Company, Division Of Conopco, Inc. Personal washing bar compositions comprising emollient rich phase/stripe
US6217887B1 (en) * 1997-06-04 2001-04-17 The Procter & Gamble Company Leave-on antimicrobial compositions which provide improved immediate germ reduction
GB9714102D0 (en) 1997-07-04 1997-09-10 Ciba Geigy Ag Compounds
US6071541A (en) * 1998-07-31 2000-06-06 Murad; Howard Pharmaceutical compositions and methods for managing skin conditions
JP3062918U (ja) * 1999-04-08 1999-10-15 株式会社タケ 化粧石鹸
JP2001097834A (ja) * 1999-09-30 2001-04-10 Yamahatsu Sangyo Kk 染毛剤組成物を充填したエアゾール製品
CA2402520A1 (fr) * 2000-03-13 2001-09-20 Kenneth Beckman Procedes et compositions biocides
JP2004500404A (ja) * 2000-03-27 2004-01-08 カール　−　ツァイス　−　シュティフツング 生物活性ガラスを含む新規化粧品、ボディケア、洗浄剤および栄養サプリメント組成物および製造方法およびその使用
AU2001268512A1 (en) * 2000-06-16 2002-01-02 Hercules Incorporated Chemically-modified peptides, compositions, and methods of production and use
EP2368445A1 (fr) * 2002-06-18 2011-09-28 Martek Biosciences Corporation Emulsions stables d'huiles dans des solutions aqueuses et procédé pour les préparer
JP4490817B2 (ja) 2002-09-12 2010-06-30 信越化学工業株式会社 新規なオルガノポリシロキサン重合物及びペースト状組成物並びにその組成物を用いた化粧料
JP2004224703A (ja) * 2003-01-20 2004-08-12 Teepol Diversey Kk 手指用殺菌洗浄剤組成物
CN100460414C (zh) * 2003-10-01 2009-02-11 第一精密化学株式会社 稳定的维生素b6衍生物
JP2006213697A (ja) * 2005-01-07 2006-08-17 Mitsui Chemicals Inc 皮膚外用剤組成物
BRPI0612513A2 (pt) * 2005-06-20 2010-11-30 Playtex Products Inc composições não irritantes
KR101047785B1 (ko) 2005-06-30 2011-07-07 (주)아모레퍼시픽 천연 연화 꽃잎을 함유하는 화장료 조성물
KR100769479B1 (ko) 2006-03-28 2007-10-23 정연철 발모성 샴푸 조성물
JP2007262039A (ja) * 2006-03-30 2007-10-11 Kose Corp 化粧料
US7985722B2 (en) * 2006-07-27 2011-07-26 Aurora Advanced Beauty Labs Rhamnolipid-based formulations
JP2008037763A (ja) * 2006-08-01 2008-02-21 Adeka Corp 抗菌剤及び抗菌剤組成物
JP5033567B2 (ja) * 2007-10-01 2012-09-26 株式会社コーセー オイルクレンジング料
JP2012020938A (ja) * 2008-11-11 2012-02-02 P & P F:Kk インフルエンザウイルス感染を予防するための泡立性の抗菌手洗い洗浄剤

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001017495A1 (fr) * 1999-09-09 2001-03-15 The Boots Company Plc Composition cosmetique contre les radicaux libres
US20090068219A1 (en) * 2007-09-10 2009-03-12 3Lab, Inc. Anti-wrinkle hormone-type cosmetic composition
JP2009067712A (ja) * 2007-09-12 2009-04-02 Arimino Kagaku Kk 毛髪変形処理用消臭剤
JP2009235022A (ja) * 2008-03-28 2009-10-15 Kose Corp マッサージ化粧料
WO2010033800A2 (fr) * 2008-09-19 2010-03-25 Alacrity Biosciences, Inc. Formulations stabilisant la tétracycline
KR20100043453A (ko) * 2008-10-20 2010-04-29 (주)아모레퍼시픽 천연색소를 함유하는 유중수형 립메이크업 조성물

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
Anonymous: "Buffers", CNR Biological Imaging Facility , 1 January 1999 (1999-01-01), page 6PP, XP002717996, University of Berkeley Retrieved from the Internet: URL:http://microscopy.berkeley.edu/Resources/instruction/buffers.html [retrieved on 2013-10-15] *
Anonymous: "The Most Popular Natural Preservatives", Natural Cosmetic News , 11 November 2009 (2009-11-11), page 7PP, XP002714800, Retrieved from the Internet: URL:http://www.naturalcosmeticnews.com/new-ingredients/the-most-popular-natural-preservatives-2/ [retrieved on 2013-10-15] *
beautifulwithbrains: "Citric Acid", beautifulwithbrains.com , 23 May 2009 (2009-05-23), page 5PP, XP002714799, Retrieved from the Internet: URL:http://beautifulwithbrains.com/2009/05/23/know-your-ingredients-citric-acid/ [retrieved on 2013-10-15] *
C. A. PHILLIPS: "The effect of citric acid, lactic acid, sodium citrate and sodium lactate, alone and in combination with nisin, on the growth of Arcobacter butzleri", LETTERS IN APPLIED MICROBIOLOGY, vol. 29, no. 6, 1 December 1999 (1999-12-01), pages 424-428, XP055083896, ISSN: 0266-8254, DOI: 10.1046/j.1472-765X.1999.00668.x *
C. G. DALY: "Anti-bacterial effect of citric acid treatment of periodontally diseased root surfaces In vitro", JOURNAL OF CLINICAL PERIODONTOLOGY, vol. 9, no. 5, 1 October 1982 (1982-10-01) , pages 386-392, XP055083864, ISSN: 0303-6979, DOI: 10.1111/j.1600-051X.1982.tb02049.x *
DATABASE GNPD [Online] MINTEL; "Cracked Heel Repair Cream", XP002714798, Database accession no. 1264258 *
LEE Y-L ET AL: "BACTERICIDAL ACTIVITY OF CITRATE AGAINST GRAM-POSITIVE COCCI", LETTERS IN APPLIED MICROBIOLOGY, vol. 33, no. 5, 1 November 2001 (2001-11-01), pages 349-351, XP001089847, OXFORD, GB ISSN: 1472-765X, DOI: 10.1046/J.1472-765X.2001.01011.X *
MATOUSEK JENNIFER L ET AL: "Evaluation of the effect of pH on in vitro growth of Malassezia pachydermatis", CANADIAN JOURNAL OF VETERINARY RESEARCH, vol. 67, no. 1, 1 January 2003 (2003-01-01), pages 56-59, XP002494884, CANADIAN VETERINARY MEDICAL ASSOCIATION, OTTAWA, CA ISSN: 0830-9000 *
NAGOBA B S ET AL: "Treatment of superficial pseudomonal infections with citric acid: An effective and economical approach", JOURNAL OF HOSPITAL INFECTION, vol. 40, no. 2, 1 October 1998 (1998-10-01), pages 155-157, XP002493914, ACADEMIC PRESS, LONDON, GB ISSN: 0195-6701, DOI: 10.1016/S0195-6701(98)90095-0 *
OJO O O ET AL: "Evaluation of antimicrobial activities of some organic acids on bacteria", DISCOVERY AND INNOVATION, vol. 17, no. 1-2, June 2005 (2005-06), pages 22-26, XP002714801, ISSN: 1015-079X *
See also references of WO2011145765A1 *
W. A. FONZI: "Role of pH response in Candida albicans virulence", MYCOSES, vol. 45, no. S1, 14 September 2002 (2002-09-14), pages 16-21, XP055084127, ISSN: 0933-7407, DOI: 10.1111/j.1439-0507.2002.tb04540.x *
WEIJMER M C ET AL: "Superior antimicrobial activity of trisodium citrate over heparin for catheter locking", NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 17, no. 12, 1 January 2002 (2002-01-01), pages 2189-2195, XP003007987, OXFORD UNIVERSITY PRESS, GB ISSN: 0931-0509, DOI: 10.1093/NDT/17.12.2189 *

Also Published As

Publication number Publication date
WO2011145765A1 (fr) 2011-11-24
CN102958520A (zh) 2013-03-06
BR112012029418A2 (pt) 2017-02-21
JP2013526565A (ja) 2013-06-24
US20130064872A1 (en) 2013-03-14
US20140140946A1 (en) 2014-05-22
CA2799393A1 (fr) 2011-11-24
EP2574338A4 (fr) 2014-02-12

Similar Documents

Publication Publication Date Title
ES2444368T3 (es) Agente con un efecto de liberación retardada para la represión de microorganismos
CN110831565B (zh) 局部用组合物
EP2110121B1 (fr) Compositions cosmétiques et dermatologiques, en particulier pour le traitement de substrats contenant de la kératine
JPH11322591A (ja) 防腐殺菌剤及び人体施用組成物
WO2003002074A1 (fr) Compositions en emulsion
KR101780863B1 (ko) 홍삼 에탄올 추출물의 부탄올 분획물을 포함하는 여드름 개선용 화장료 조성물
CN108366936A (zh) 宠物护理组合物
US20140140946A1 (en) Skin preparation composition for external use with excellent antibacterial and antifungal effects
JP2011074082A (ja) 防腐殺菌剤及び人体施用組成物
JP2000247892A (ja) 製剤組成物
JP2002193755A (ja) フケ・カユミ防止頭髪用および洗髪用化粧料
JP4734293B2 (ja) 防腐殺菌剤及び人体施用組成物
JPH11255612A (ja) 抗菌剤及び抗菌性組成物
CN109010157A (zh) 一种6-氟咪唑并吡啶衍生物的用途
JP2005232125A (ja) 防腐殺菌剤並びに該防腐殺菌剤を配合した化粧品、医薬品及び食品
EP3648735B1 (fr) Nouvelle utilisation
JPH1045557A (ja) 抗菌性低刺激化粧料
CN114366680A (zh) 用于养护头皮健康防脱固发的洗发组合物及其制备方法
KR101171104B1 (ko) 항균 및 항진균 효과가 우수한 피부 외용제 조성물
CN109939090A (zh) 新颖的用途
KR101845308B1 (ko) 염화마그네슘을 함유하는 전신 세정용 고체 세정제 조성물 및 그 제조방법
KR102599093B1 (ko) 편백나무가지 추출물을 유효성분으로 포함하는 기능성 화장료 조성물
CN105342868A (zh) 胡萝卜素二合一香波
JP4294393B2 (ja) 防腐殺菌剤並びに該防腐殺菌剤を配合した化粧料、医薬品及び食品
JP2009196969A (ja) 皮膚外用剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20121220

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61Q 19/10 20060101ALI20131105BHEP

Ipc: A61Q 5/02 20060101ALI20131105BHEP

Ipc: A61K 31/19 20060101AFI20131105BHEP

Ipc: A61Q 1/06 20060101ALI20131105BHEP

Ipc: A61P 17/00 20060101ALI20131105BHEP

Ipc: A61P 31/10 20060101ALI20131105BHEP

Ipc: A61P 31/04 20060101ALI20131105BHEP

Ipc: A61K 8/02 20060101ALI20131105BHEP

Ipc: A61K 31/195 20060101ALI20131105BHEP

Ipc: A61K 31/66 20060101ALI20131105BHEP

Ipc: A61Q 19/00 20060101ALI20131105BHEP

Ipc: A61K 8/365 20060101ALI20131105BHEP

Ipc: A61K 33/42 20060101ALI20131105BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/19 20060101AFI20131220BHEP

Ipc: A61Q 19/00 20060101ALI20131220BHEP

Ipc: A61Q 1/06 20060101ALI20131220BHEP

Ipc: A61K 8/02 20060101ALI20131220BHEP

Ipc: A61P 31/10 20060101ALI20131220BHEP

Ipc: A61Q 19/10 20060101ALI20131220BHEP

Ipc: A61K 31/195 20060101ALI20131220BHEP

Ipc: A61K 33/42 20060101ALI20131220BHEP

Ipc: A61Q 5/02 20060101ALI20131220BHEP

Ipc: A61P 17/00 20060101ALI20131220BHEP

Ipc: A61P 31/04 20060101ALI20131220BHEP

Ipc: A61K 31/66 20060101ALI20131220BHEP

Ipc: A61K 8/365 20060101ALI20131220BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20140114

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140812